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Abstract 
The N-terminal domain of hnRNP A1 protein, termed UP1, 
comprises two tandem RNA-recognition motifs, both of 
which are necessary for efficient RNA binding and for the 
alternative splicing activity of hnRNP A1. Recombinant 
human UPI expressed in E. coli has been crystallized in 
space group P2~ with unit-cell dimensions a=37.94,  
b = 43.98, c = 55.64 A, and 13 = 93.9 °. The unit-cell volume 
is consistent with one UP1 molecule per asymmetric unit and 
a calculated 49% solvent content. The crystal diffraction 
limit is higher than 1.3A, and a data set to 2.0A, has been 
collected. Diffraction data from one platinum and two 
mercury derivatives have also been collected. 
1. Introduction 
A1 heterogeneous nuclear ribonucleoprotein (hnRNP A1) is 
one of the most abundant hnRNP proteins, which associate 
with nascent ranscripts in the nucleus (Dreyfuss, Matunis, 
Pifiol-Roma & Burd, 1993). It has been shown to influence 
alternative 5' splice site selection by antagonizing the activity 
of SF2/ASF and SC35, leading to the activation of distal 5' 
splice sites and promoting alternative xon skipping (Fu, 
Mayeda, Maniatis & Krainer, 1992; Mayeda & Krainer, 
1992; Mayeda, Helfman & Krainer, 1993). In addition, 
hnRNP A I facilitates the efficient annealing of complemen- 
tary RNA or DNA molecules in vitro (Kumar & Wilson, 
1990; Pontius & Berg, 1990; Munroe & Dong, 1992; 
Portman & Dreyfuss, 1994), which may directly facilitate 
base-pairing interactions between snRNA's and pre-mRNA. 
hnRNP A1 can interact stably with U2 and U4 snRNP's in 
vitro, but not with U I snRNP (Buvoli, Cobianchi & Riva, 
1992). The interaction with U2, together with the association 
between hnRNP A1 and certain 3' splice sites in vitro 
(Swanson & Dreyfuss, 1988) suggested a potential role for 
hnRNP A1 in the binding of U2 snRNA to the branch site in 
the early stages of spliceosome assembly (Buvoli et al., 
1992). 
Human hnRNP A1 is a 34 kDa protein consisting of a 
single polypeptide chain of 320 amino acids. An N- 
terminal proteolytic fragment spanning the first 196 amino 
acids and known as unwinding protein 1 (UP1; Herrick & 
Alberts, 1976; Williams, Stone, LoPresti, Merrill & 
Planck, 1985) comprises two RNA-recognition motif 
(RRM) sequences eparated by a short linker. The C- 
terminal region of hnRNP A I is rich in glycine and 
includes several RGG repeats, which also constitute an 
RNA-binding motif (Kiledjian & Dreyfuss, 1992). Early 
studies showed that both the N-terminal UP1 domain and 
the C-terminal glycine-rich domain are capable of binding 
to nucleic acids, whereas the intact protein exhibits more 
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stable and highly cooperative binding, with cooperativity 
being the result of self-association of the C-terminal 
domain (Merrill, Stone, Cobianchi, Wilson & Williams, 
1988; Cobianchi, Karpel, Williams, Notario & Wilson, 
1988; Kumar et al., 1990; Casas-Finet et al., 1993). Both 
the UP1 domain and the C-terminal domain are required 
for the alternative splicing activity of hnRNP A1, and 
within the UP1 domain, mutations in conserved surface 
residues of either RRM abolish activity, although general 
RNA binding is not substantially affected (Mayeda, 
Munroe, Cficeres & Krainer, 1994). Purified hnRNP AI 
binds with high affinity to short RNA's containing one or 
more copies of the motif UAGGGA/U (Burd & Dreyfuss, 
1994), although the physiological significance of this high- 
affinity binding remains controversial (Abdul-Manan, 
O'Malley & Williams, 1996). A 38-amino-acid domain 
near the C-terminus, termed M9, has been shown to be 
both necessary and sufficient for the nuclear localization of 
hnRNP A1 (Siomi & Dreyfuss, 1995). In addition, M9 is 
also a nuclear export signal (Michael, Choi & Dreyfuss, 
1995), responsible for the shuttling of hnRNP A1 between 
the nucleus and the cytoplasm (Pifiol-Roma & Dreyfuss, 
1992). 
The RRM is an ancient and extremely common RNA- 
binding motif (reviewed in Birney, Kumar & Krainer, 
1993). Many proteins with RRM's have two, three, or 
four copies of the motif, and of these some, but not all, 
require more than one RRM for stable and specific RNA 
binding. The tertiary structures of several isolated RRM's 
have been recently determined, including the crystal and 
solution structure of the first of two RRM's in the U1 
snRNP A polypeptide (Nagai, Oubridge, Jessen, Li & 
Evans, 1990; Hoffman, Query, Golden, White & Keene, 
1991) and its co-crystal structure with bound RNA 
(Oubridge, Ito, Evans, Teo & Nagai, 1994), the NMR 
structure of the RRM of hnRNP C1/C2 with and without 
bound RNA (Wittekind, G6rlach, Friedrichs, Dreyfuss & 
Mueller, 1992; G6rlach, Wittekind, Beckman, Mueller & 
Dreyfuss, 1992) and the NMR structure of the second 
RRM of Sex-lethal (Lee, Kanaar, Rio & Wemmer, 
1994). The secondary structure and folding topology of 
the first RRM of hnRNP A1 have also been solved by 
NMR (Garrett et al., 1994). However, no structures with 
two or more RRM's have been determined to date. We 
hope that the three-dimensional structure of UP1 will not 
only facilitate the understanding of the structural basis of 
the RNA-binding specificity and alternative splicing 
activity of hnRNP A1, but also shed light on how 
synergy between RRM's may arise in other proteins with 
multiple RRM's. Here we report the crystallization and 
preliminary X-ray analysis of the UP1 domain of hnRNP 
A1. 
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2. Materials and methods 
2.1. Overexpression a d purification 
The plasmid pET9d-UP1, which allows overexpression f 
the first 196 amino acids of human hnRNP A1 from a cDNA 
fragment cloned into the T7 expression vector pET-9d 
(Studier, Rosenberg, Dunn & Dubendorff, 1990), has been 
described (Mayeda et al., 1994). BL21(DE3)pLysS E. coli 
cells carrying the pET9d-UP1 plasmid were grown in LB 
medium containing kanamycin (1001.tgm1-1) and chloram- 
phenicol (25 lxgm1-1) at 310K to an OD600 between 0.8 and 
1.0, at which point isopropyl /%D-thiogalactopyranoside 
(IPTG) was added to a final concentration of 0.4mM, and 
the temperature was reduced to 298 K. After 18 h, cells were 
harvested by centrifugation, washed, and stored at 203K 
before use. 
All purification steps were carried out at 277K. The 
frozen cell pellet from a 21 culture was thawed, resuspended 
in 40ml of lysis buffer [20mM HEPES pH 7.5, 100mM 
NaC1, 5% glycerol, lmM EDTA, lmM EGTA, lmM 
phenylmethylsulfonyl fluoride (PMSF) and 0.1% /~-mercap- 
toethanol (BME)], and the cells were lysed by sonication. 
Cellular debris were removed by centrifugation and the 
cleared supernatant was brought o 50% ammonium sulfate 
saturation by slow addition of solid ammonium sulfate with 
gentle stirring. The precipitate was removed by centrifuga- 
tion after 1 h incubation, and the cleared supernatant was 
diluted with lysis buffer to a final ammonium sulfate 
concentration of 40% saturation, prior to loading onto a 
50ml Phenyl-Sepharose column (Pharmacia). UP1 eluted 
from the column at approximately 12% saturated ammonium 
sulfate in a 40-0% linear gradient. Fractions containing UP1 
were analyzed by sodium dodecyl sulfate polyacrylamide g l 
electrophoresis (SDS-PAGE), pooled and dialyzed twice 
against 21 of buffer B (20mM MES pH 6.0, 5% glycerol, 
50 mM NaC1, 1 mM EDTA, 0.1% BME), and then loaded 
onto a 40ml Heparin-agarose column (Bio-rad). UP1 eluted 
from the column at approximately 300 mM NaC1 in a linear 
50mM-1M gradient. Fractions containing UP1 were ana- 
lyzed by SDS-PAGE, pooled and concentrated in Centricon 
(Amicon) concentrators to 15-20 mgml -~ for crystallization. 
Typically, a 21 culture yielded approximately 30mg of 
protein of sufficient purity for crystallization. 
2.2. Crystallization and preparation of heavy-atom deriva- 
tives 
Initial crystallization conditions were determined using the 
sparse-matrix screening method (Jancarik & Kim, 1991) by 
the hanging-drop vapor-diffusion technique (McPherson, 
1982). After initial crystals were observed, the concentra- 
tions of precipitant, salt, and pH were carefully refined to 
reach optimal conditions. The best diffracting crystals were 
grown at 289K in a 61xl hanging drop containing equal 
volumes of protein solution (15 mg m1-1 or higher in 300 mM 
NaCI, 20 mM MES, pH 6.0, 1 mM EDTA, 0.1% BME) and 
mother liquor [25% polyethylene glycol (PEG) 4000, 20% 2- 
methyl-2,4-pentanediol (MPD) or 10-15% glycerol, 100mM 
Tris, pH 8.5]. Needle-like crystals appeared within a few 
hours after protein and precipitant were mixed. The crystals 
reached their maximum size of approximately 
0.1 x 0.1 x 1.0mm after 3d (Fig. 1). Heavy-atom deriva- 
tives were prepared by transferring individual crystals into 
6 ~tl mother liquor droplets on cover slips, and 3 l.tl of 5 mM 
mercurial or platinum compound solutions were introduced 
into the crystal-containing droplets. The crystals were soaked 
for 24-48 h before being subjected to the X-ray beam. 
2.3. X-ray data collection 
UP1 crystal diffraction data were collected at beamline 
X12C using an imaging-plate detector (MAR Research) at 
the National Synchrotron Light Source (NSLS), Brookhaven 
National Laboratory (BNL). UP1 crystals are susceptible to 
radiation damage at room temperature. Therefore, all data were 
collected at 100 K using an Oxford Cryosystems Cryostream 
cryocooling system. Individual crystals were picked up in nylon 
cryo-loops and directly dipped into liquid nitrogen before 
mounting the loops onto the goniometer head under a 100 K 
gaseous nitrogen stream. Images were indexed, integrated 
and scaled using the HKL suite of programs (Otwinowski, 
1993). The space-group determination was further aided by a 
pseudo-precession display program, PRECESS, of the 
PHASES program suite (Furey & Swaminathan, 1997). 
For heavy-atom derivative data collection, derivatization 
of the crystals was monitored prior to data collection by 
measuring the X-ray fluorescence while scanning the 
wavelength around the/-,in absorption edges of Hg and Pt, 
for crystals soaked with mercurial and platinum compound 
solutions, respectively. When collecting derivative data sets, 
the incident X-ray wavelength was adjusted to a position 
corresponding to the absorption peak for the heavy atom 
used in order to maximize the anomalous differences, which 
will be used for phasing. 
3. Results and discussion 
The UP1 crystals belong to space group P21 with cell 
dimensions a = 37.94, b = 43.98, c = 55.64 ./k and 
13=93.9 ° . From the predicted molecular mass of 
22 264 Da and the crystal unit-cell volume, we determined 
that there is one molecule per asymmetric unit with a V u of 
2.1 ,h3 Da-1, and a calculated solvent content of 49%. The 
solvent content was obtained by the method described by 
Fig. 1. Crystals of recombinant human UP1 protein. The largest 
crystal is approximately 0.1 mm in width and 1 mm in length. 
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Matthews (1985), using a partial specific volume of 
0.762mlg -1 calculated from the amino-acid composition 
(Perkins, 1986) and the anhydrous crystallographic residue 
volumes derived from intact proteins (Chothia, 1975). 
UP1 crystals diffracted XTrays strongly. At least in one 
case, diffraction beyond 1.3 A resolution was observed (Fig. 
2). Unfortunately, a high-resolution data set from this crystal 
was not collected because of the presence of satellite spots 
when it was rotated away from the initial orientation. 
Instead, a 2.0,~, data set was collected from a second crystal. 
This data set is 98.1% complete (1/0. > 0, 86% complete in 
the highest resolution shell of 2.03-2.00A) with an overall 
Rmerg e o f  5 .2  %. 
To solve the phase problem, we first tried the molecular 
replacement method using the crystal structure of the N- 
terminal RRM of U1A (Nagai et al., 1990) as the search 
model. However, no significant rotational and translational 
solutions were found. Next, we soaked the crystals in 
1.7mM K2PtC14 solution for 48h and collected a 2.4A data 
set with a 98.6% (1/0. > 0) completeness and an Rmerg e of 
4.1%. This derivative showed one very strong peak (12o') in 
the V - -1 /2  section of the anomalous difference Patterson 
map. However, the isomorphous difference between the 
derivative and the native data set was significant only at a 
resolution lower than 4A.. In the meantime, we have 
obtained two mercurial derivatives from p-chloromercuri- 
benzene sulfonate (PCMBS) and methyl mercuric chloride 
(MMC) soaks. Both PCMBS and MMC derivatives have two 
metal sites, with nearly identical positions between the two 
derivatives. However, the relative occupancy between the 
two sites in the MMC derivative appears to be different from 
that in the PCMBS derivative. Therefore, the MMC 
derivative may contribute additional phasing information 
even though it has redundant metal positions. A 2.5A, 
Fig. 2. A section of a 1.5 ° oscillation diffraction pattern collected at 
beamline X12C of NSLS, BNL, recorded with a 30cm diameter 
MAR imaging-plate d tector at a distance of 145 nun, 2 = 1.0 A and 
90 s exposure time. The resolution at the edge of the photograph 
corresponds to 1.28 A. 
PCMBS derivative data set was collected at 2 ---- 1.0 A, with a 
96.3% completeness (1/0. > 1.0) and an Rmerg e of 8.6%. 
Similarly, a 2.5 A MMC derivative data set was collected at 
2 = 1.0078A with a 98.4% completeness (1/0. > 1.0) and an 
Rrnerg e o f  5 .9%.  
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Fig. 3. (a) V ---- I/2 section of the PCMBS isomorphous difference 
map at 2.5 A resolution, contoured at lot interval starting at 3~. (b.) 
The same section for the anomalous difference map at 2.5A 
resolution with same contouring. 
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In summary, we have crystallized the recombinant human 
UPI protein fragment. UP1 crystals diffract X-rays strongly, 
and two mercurial isomorphous derivatives have been 
obtained. These diffraction data should enable us to solve 
the phase problem for structure determination, which is 
currently in progress and will be reported elsewhere. 
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